Maturation of dendritic cells by bacterial immunomodulators
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15246609
DOI
10.1016/j.vaccine.2004.01.006
PII: S0264410X04000398
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic chemistry pharmacology MeSH
- Antigens, Surface analysis MeSH
- Bacteria chemistry MeSH
- Stimulation, Chemical MeSH
- Cytokines analysis biosynthesis MeSH
- Dendritic Cells drug effects MeSH
- Dextrans MeSH
- Endocytosis MeSH
- Phagocytosis drug effects MeSH
- Phenotype MeSH
- Fluorescein-5-isothiocyanate MeSH
- Interleukin-10 biosynthesis MeSH
- Interleukin-12 biosynthesis MeSH
- Culture Media MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Flow Cytometry MeSH
- Reproducibility of Results MeSH
- T-Lymphocytes drug effects immunology MeSH
- Lymphocyte Culture Test, Mixed MeSH
- Antibody Formation drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Antigens, Surface MeSH
- Cytokines MeSH
- Dextrans MeSH
- Fluorescein-5-isothiocyanate MeSH
- Interleukin-10 MeSH
- Interleukin-12 MeSH
- Culture Media MeSH
Dendritic cells (DC) become fully functional upon maturation by various stimuli. We tested whether an immunostimulatory effect of clinically used immunomodulators (Luivac, Biostim, Ribomunyl, Imudon, Bronchovaxom) is caused by direct DC activation. We found that Luivac, Biostim and Ribomunyl have a very high DC stimulatory potential in vitro. The level of DC activation was comparable or higher than DC maturation induced by standard maturation stimuli, Poly (I:C) or lipopolysaccharide. Treated DC had activated phenotype, reduced phagocytic activity and they induced the proliferation of allogeneic T lymphocytes. These results are important for understanding the physiology of action of these widely prescribed agents. Administration of bacterial immunomodulators should be considered with care to avoid the potential risk of inducing an autoimmune disease. They could also be used as well-defined maturating agents in the protocols used for the ex vivo production of DC-based vaccines for clinical trials.
References provided by Crossref.org
